Home/Pipeline/26F1 AAV Gene Therapy

26F1 AAV Gene Therapy

Parkinson's Disease

PreclinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical

Status

Active

Company

Syngle Therapeutics

About Syngle Therapeutics

Syngle Therapeutics is an early-stage biotech developing a novel gene therapy-based immunotherapy for Parkinson's disease, targeting toxic alpha-synuclein oligomers. Its lead asset, antibody 26F1, is in preclinical development and is protected by a patent application. The company was founded as a spin-out from Crossbeta Biosciences, has received grant support from The Michael J. Fox Foundation, and is led by a team with deep experience in gene therapy, neurodegeneration, and biotech finance. Syngle aims to address a significant unmet need for a disease-modifying treatment in a large and growing neurodegenerative market.

View full company profile

Therapeutic Areas

Parkinson's Disease Synucleinopathies

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active
golexanolone	Umecrine Cognition	Preclinical	Active
Parkin Activator Program	Progenra	Pre-clinical	Active
Not Specified	Asceneuron	Not Disclosed	Active